A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

Future Oncol · 2025 · PMC12758334 · PMID 41313045

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

What were the results of the study? In people with mCRPC, combined treatment with enzalutamide plus ADT and radium-223 showed a trend towards an increased time that patients lived without their cancer getting worse compared with enzalutamide plus ADT alone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.